Pure Global AI
NCT06346808Not yet recruiting

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer
Sichuan UniversityPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Oncolytic virus Plus Anti-PD1 and Chemotherapy
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan University
Location
Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
May 01, 2027
Enrollment
20 participants
Primary outcome

Incidence of Treatment-Related Adverse Events [Safety and Tolerability]

Summary

The aim of this single center, single arm and prospective study is to explore the safety and
 efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for
 Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06346808
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06346808 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sichuan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.